Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.
06855.HK stock price ended at $47.5 on 金曜日, after rising 2.41%
On the latest trading day Feb 13, 2026, the stock price of 06855.HK rose by 2.41%, climbing from $46.36 to $47.50. Throughout the session, the stock experienced a volatility of 4.12%, with prices fluctuating between a daily low of $45.62 and a high of $47.50. Alongside this price increase, trading volume also rose by 544.4K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 778.7K shares were traded, amounting to a market value of approximately $17.6B.